机构：[1]Department of Urology Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University Chengdu China.四川大学华西医院[2]Department of Pathology West China Hospital, Sichuan University Chengdu China.
Dear Editor
Following transurethral resection of bladder tumor (TURBT),
intravesical Bacille Calmette-Guerin (BCG) instillation remains
the gold-standard adjuvant immunotherapy for high-risk nonmuscle-invasive bladder cancer (HR-NMIBC). However, 5-year
recurrence and progression rates still reach 58% and 35%, respectively, among HR-NMIBC patients receiving BCG [1]. Human
epidermal growth factor receptor 2 (HER2) overexpression has
been identified as an independent predictor of poor response
to BCG in NMIBC. Patients with HR-NMIBC and HER2 overexpression exhibited a higher risk of disease recurrence and
progression following BCG treatment [1]. Disitamab vedotin (DV;
RC48-ADC) is a HER2-targeted antibody–drug conjugate (ADC)
comprising a humanized HER2-directed antibody conjugated to
monomethyl auristatin E via a cleavable linker [2]. Clinical trials
have demonstrated promising efficacy and manageable safety
of DV in metastatic urothelial carcinoma patients with HER2
overexpression [3]. This cohort study aims to compare the efficacy
of DV and BCG in HR-NMIBC patients with immunohistochemistry (IHC)-confirmed HER2 overexpression and evaluate
the relationship between HER2 expression and tumor immune
profiles.
基金：
the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. 0040205301E21) and Beijing
Xisike Clinical Oncology Research Foundation (Y-Gilead2024-ZD-0226).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|1 区医学
小类|1 区医学：研究与实验
最新[2025]版：
大类|1 区医学
小类|1 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Urology Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University Chengdu China.
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Haoyang,Chen Junru,Zhu Qiyu,et al.Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression[J].Medcomm.2025,6(10):e70427.doi:10.1002/mco2.70427.
APA：
Liu Haoyang,Chen Junru,Zhu Qiyu,Liu Haolin,Chuang Yeechun...&Zeng Hao.(2025).Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.Medcomm,6,(10)
MLA：
Liu Haoyang,et al."Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression".Medcomm 6..10(2025):e70427
医学